Shares of Verona Pharma plc (NASDAQ:VRNA), a clinical-stage biopharmaceutical company focused on respiratory disease treatments, plummeted 5.95% in the pre-market trading session on Friday.
The stock's decline comes despite an analysis article suggesting that Verona Pharma is expected to break even in 2025 and become profitable in 2026, according to consensus estimates from industry analysts covering the company. The article highlights that analysts forecast an average annual growth rate of 59% for Verona Pharma to achieve profitability, which is considered optimistic.
However, the article also notes that Verona Pharma has a relatively high level of debt, with debt exceeding 92% of its equity. This high debt obligation increases the risk for investors in the loss-making company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。